Literature DB >> 26069928

Styryl-N-phenyl-N'-(2-chloroethyl)ureas and styrylphenylimidazolidin-2-ones as new potent microtubule-disrupting agents using combretastatin A-4 as model.

Mathieu Gagné-Boulet1, Sébastien Fortin2, Jacques Lacroix1, Carole-Anne Lefebvre1, Marie-France Côté1, René C-Gaudreault3.   

Abstract

Combretastatin A-4 (CA-4) is a well-studied and attractive molecular template to develop new antimitotics. Several thousand of modifications were performed on the ring B and the ethenyl bridge of CA-4 but only a few involved the trimethoxyphenyl moiety (TMP, ring A) often considered essential to the antiproliferative and antimicrotubule activities. In this study, we described the design, the preparation, the characterization and the biological evaluation of three new series of CA-4 analogs namely styryl-N-phenyl-N'-ethylureas (SEUs), styryl-N-phenyl-N'-(2-chloroethyl)ureas (SCEUs) and styrylphenylimidazolidin-2-ones (SIMZs) bearing a 3-Cl (series a), 3,5-Me (series b) and TMP (series c) substituents, respectively. All SCEU and SIMZ Z-isomers were active in the high and the low nanomolar range, respectively. Conversely to SEUs and their E-isomers that were significantly less active or inactive. Interestingly, the TMP moiety is giving rise to derivatives exhibiting the lowest antiproliferative activity in the SCEU series (10c) and the most active compound in the SIMZ series (12c). Moreover, SIMZ Z-isomers bearing either a 3-Cl (12a) or a 3,5-Me (12b) exhibited antiproliferative activities that are also in the same order of magnitude as 12c. All SCEU and SIMZ Z-isomers also arrested the cell cycle progression in G2/M phase, bound to the colchicine-binding site and disrupted the cytoskeleton of cancer cells. In addition to the promising and innovative microtubule-disrupting properties of SCEUs and SIMZs, these results show that the TMP moiety is not essential for the cytocidal activity of these new CA-4 analogs.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Antimitotics; Colchicine-binding site inhibitors; Combretastatin A-4; Styryl-N-phenyl-N′-(2-chloroethyl)ureas; Styryl-N-phenyl-N′-ethylureas; Styrylphenylimidazolidin-2-ones

Mesh:

Substances:

Year:  2015        PMID: 26069928     DOI: 10.1016/j.ejmech.2015.05.034

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  4 in total

Review 1.  New Potential Agents for Malignant Melanoma Treatment-Most Recent Studies 2020-2022.

Authors:  Paweł Kozyra; Danuta Krasowska; Monika Pitucha
Journal:  Int J Mol Sci       Date:  2022-05-29       Impact factor: 6.208

2.  Urea Derivatives in Modern Drug Discovery and Medicinal Chemistry.

Authors:  Arun K Ghosh; Margherita Brindisi
Journal:  J Med Chem       Date:  2019-12-02       Impact factor: 7.446

3.  Novel Trifluoromethylcoumarinyl Urea Derivatives: Synthesis, Characterization, Fluorescence, and Bioactivity.

Authors:  Lili Qiao; Shuanghong Hao
Journal:  Molecules       Date:  2018-03-07       Impact factor: 4.411

4.  Structure-Activity Relationship Studies of β-Lactam-azide Analogues as Orally Active Antitumor Agents Targeting the Tubulin Colchicine Site.

Authors:  Dong-Jun Fu; Ling Fu; Ying-Chao Liu; Jun-Wei Wang; Yu-Qing Wang; Bing-Kai Han; Xiao-Rui Li; Chuang Zhang; Feng Li; Jian Song; Bing Zhao; Ruo-Wang Mao; Ruo-Han Zhao; Sai-Yang Zhang; Li Zhang; Yan-Bing Zhang; Hong-Min Liu
Journal:  Sci Rep       Date:  2017-10-06       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.